Neuromodulation for Ulcerative Colitis

Recruiting in Palo Alto (17 mi)

+2 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Boomerang Medical

No Placebo Group

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?

The BOOM-IBD2 clinical trial is designed to evaluate the effectiveness of sacral neuromodulation for the treatment of IBD.

Research Team

Eligibility Criteria

This trial is for men and women aged 18 to 85 who have been diagnosed with ulcerative colitis. Participants must be able to consent, follow the study's procedures, and attend all follow-ups. They should still have their entire colon intact.

Inclusion Criteria

I am either male or female.

I am between 18 and 85 years old.

I have been diagnosed with ulcerative colitis.

Treatment Details

Interventions

• Neuromodulation (Neuromodulation)

Trial Overview The BOOM-IBD2 trial is testing sacral neuromodulation, a technique that uses electrical stimulation to manage symptoms of ulcerative colitis.

Participant Groups

Group I: Treatment Arm Experimental Treatment 1 Intervention

Patients implanted with neuromodulation

Neuromodulation is already approved in Canada, Japan for the following indications:

Approved in Canada as Neuromodulation Therapy for:

• Chronic Neuropathic Pain
• Epilepsy
• Parkinson's Disease

Approved in Japan as Neuromodulation Therapy for:

• Chronic Neuropathic Pain
• Parkinson's Disease

Who Is Running the Clinical Trial?

Boomerang Medical

Lead Sponsor

Trials

2

Recruited

180+